Caas Capital Management LP Chinook Therapeutics, Inc. Call Options Transaction History

Caas Capital Management LP

  • $1.31 Billion
  • Q1 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding KDNY

# of Institutions
4
Shares Held
234K
Call Options Held
0
Put Options Held
0
View Full List

About CHINOOK THERAPEUTICS, INC.

KDNY Quotes by TradingView
  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email